SPECIALIZED CENTER OF RESEARCH IN HYPERBARIC OXYGEN THER

描述（申请人摘要）：本申请是一个新的程序 这是一项多学科的努力， 高压氧（HB 02）的作用、安全性和临床疗效 疗法HB02 Hercules已被指定为免费或替代 国家补充和替代医学中心的模式。 该计划包括4个研究项目和3个支持核心， 中心假设：HB02治疗将有益于头颈癌 放射治疗后必须接受重建手术的患者 因为，在药理学剂量下，氧气会增强血管生成， 特定类型的细胞间粘附。四个领域的共同主题 研究项目是生物学和临床反应海拔 头部和颈部肿瘤、内皮细胞、巨噬细胞和 中性粒细胞项目1将开发一个预测模型， 由于癌症需要喉切除术的患者，验证模型并评估 HB02治疗改善结局的疗效。刺激血管生成 在项目1和项目2中，均假设了HB02在辐照组织中的作用。缺氧 两个项目中的血供和血供不足将通过以下方式直接评价： 活检样品的组织病理学分析， 02-硝基咪唑化合物EF-5与组织的依赖性结合。计划2 将评估HB02在受辐射小鼠中的血管生成机制， 肿瘤异种移植物生长反应。项目3提出，高架部分 O2的压力将减少转移性头颈部肿瘤细胞， 防止中性粒细胞附着在肺内皮上。项目4建议， HB 02增加第二信使一氧化氮的内源性产生 这反过来又可能在本方案研究的许多反应中发挥作用。 科学核心是生物统计学和数据管理（核心B）和腔室， 高压设备（核心C）。整个项目将由一个 核心A（Core A）。该项目将提供新的 深入了解HB02的机制，并评估临床使用的安全性。

DESCRIPTION (Applicant's Abstract): This application is for a new program that represents a multidisciplinary effort to investigate the mechanisms of action, safety and clinical efficacy of Hyperbaric Oxygen (HB02) Therapy. HB02 herapy has been designated a complimentary or alternative modality by the National Center for Complementary and Alternative Medicine. This program consists of 4 Research Projects and 3 Support Cores which are centered on the hypothesis that: HB02 therapy will benefit head and neck cancer patients who must undergo reconstructive surgery after radiation therapy because, at pharmacological doses, oxygen augments angiogenesis and impedes specific types of intercellular adherence. Common themes within the four research projects are the biology and clinical responses to elevations in ambient 02 concentration of head and neck tumors, endothelium, macrophages and neutrophils. Project 1 will develop a predictive model for surgical risk among patients requiring laryngectomy due to cancer, validate the model and assess the efficacy of HB02 therapy for improving outcome. Stimulation of angiogenesis in irradiated tissue by HB02 is hypothesized in both Projects 1 and 2. Hypoxia and hypovascularity in both projects will be directly evaluated by histopathological analysis of biopsy samples and by a novel method, 02-dependent binding to tissues of the nitroimidazole compound EF-5. Project 2 will evaluate the mechanism for angiogenesis by HB02 in irradiated mice and tumor xenograft growth responses. Project 3 proposes that elevated partial pressures of 02 will reduce metastatic head and neck tumor cells and neutrophils from attaching to pulmonary endothelium. Project 4 proposes that HB02 increases the endogenous production of nitric oxide, a second messenger that, in turn, may play a role in many responses studied in this program. Scientific cores are Biostatistics and Data Management (Core B) and Chamber and High Pressure Equipment (Core C). The entire program will be supported by an administrative core (Core A). This coordinated program will provide new insights into mechanisms for HB02 and assess safety for clinical use.